designer491
- BioXcel Therapeutics (BTAI) filed for Chapter 11 and agreed to sell substantially all of its assets, with Teva Pharmaceuticals (TEVA) serving as the stalking horse bidder.
- The assets include BioXcel’s IGALMI treatment and its pending BXCL501 application for potential at-home